Claim OwnershipOri Spotlight
Subscribed: 3Played: 57
Subscribe
© Ori Biotech
Description
Ori Spotlight covers the latest in cell and gene therapy.
Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments.
Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect
Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments.
Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect
49 Episodes
Reverse
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Warner Biddle, CEO of Kyverna Therapeutics, to explore how autologous CAR-T therapies can be delivered safely, efficiently, and at scale in autoimmune disease.Warner shares Kyverna’s approach to designing a commercially viable treatment model — one that prioritizes outpatient care, streamlined manufacturing, and real-world practicality. They discuss what it means to bring complex therapies into community settings, how Kyverna is tailoring its rollout strategy by indication, and why the future of CAR-T in autoimmune disease depends as much on delivery as it does on data.Connect with Warner: https://www.linkedin.com/in/warnerbiddle/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Lavakumar (Kumar) Karyampudi, Senior Director of Cell Therapies at Moffitt Cancer Center, to discuss how academic institutions are evolving to meet the demands of early-phase CGT trials.Kumar shares how Moffitt is building flexible, end-to-end infrastructure that supports the full development cycle – from translational research to GMP manufacturing. Together, they explore how tighter integration between scientists, clinicians, and operational teams can accelerate first-in-human trials, why academic centres play a crucial role in advancing CGTs, and how the right partnerships can extend institutional capabilities.Connect with Kumar: https://www.linkedin.com/in/lavakumar-karyampudi/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Henrik Andersen, former SVP and Head of Cell Therapy Technology Development at Bristol Myers Squibb, to explore how early planning, automation, and economic discipline can help scale the impact of cell therapies.Henrik draws on his experience in both biologics and cell therapy to discuss how platform thinking, target product profiles, and cost-of-goods modelling can be applied earlier in development. Together, they reflect on the pitfalls of rushing to clinic without a viable manufacturing strategy, the shift in investor expectations, and why adapting lessons from biologics could help CGT companies avoid costly detours on the path to commercial success.Connect with Henrik
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Arsalan Arif, founder of Endpoints News, for a wide-ranging conversation on the business of biotech. From his early days bootstrapping a media company to Endpoints’ recent partnership with the Financial Times, Arsalan shares his journey and reflections on what it takes to build trust in an evolving industry.Together, they unpack today’s cell and gene therapy landscape, where clinical success alone isn’t enough. Arsalan offers his perspective on investor sentiment, why scaling remains the biggest challenge in CGT, and how economic models, not efficacy, will shape the next chapter of growth.Learn more about Arsalan: https://www.linkedin.com/in/arsalanarif/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Dr. Julie Allickson, Chief Technology Officer for Mayo Clinic's Center for Regenerative Biotherapeutics. With over 30 years pioneering regenerative medicine - from early bone marrow transplant programs to today's cutting-edge cell and gene therapies - Julie shares her journey and insights on translating innovative therapies from discovery to clinical impact.Together, they explore how academic medical centers are evolving to bridge the gap between research and commercialization through integrated manufacturing capabilities, multi-site clinical trials, and strategic partnerships. Julie discusses Mayo Clinic's approach to managing 30+ clinical trials across three sites, the critical role of automation and AI in reducing costs and improving scalability, and why thinking about commercial viability early in development is essential widespread patient access.Learn more: https://www.linkedin.com/in/julie-g-allickson-phd-76129062/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes back Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, for the second part of the discussion on building robust and scalable cell therapy manufacturing systems. Together, they explore how applying principles like the Theory of Constraints, designing smarter facility layouts, and implementing digital systems can reduce bottlenecks and improve throughput.Aaron brings over 20 years of experience leading manufacturing, engineering and supply chain operations across biologics and cell therapy. We’re grateful for his insights as the industry works to deliver more consistent, cost-effective therapies to patients at scale.Learn more: https://www.linkedin.com/in/aaronvernon/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, for a two-part discussion on building robust and scalable cell therapy manufacturing systems. Together they explore how applying principles like the Theory of Constraints, designing smarter facility layouts, and implementing digital systems can reduce bottlenecks and improve throughput.Aaron brings over 20 years of experience leading manufacturing, engineering and supply chain operations across biologics and cell therapy. We’re grateful for his insights as the industry works to deliver more consistent, cost-effective therapies to patients at scale.Learn more: https://www.linkedin.com/in/aaronvernon/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Amritha Jaishankar, Executive Director of the Cell and Gene Therapy Center at IQVIA, to discuss how data integration and decentralized manufacturing are reshaping access to advanced therapies.
Amritha shares her insights on how to overcome systemic challenges in cell and gene therapy, including data silos, workforce gaps, and manufacturing inefficiencies. Together, they explore the transformative potential of community sites, digital platforms and collaborative partnerships in driving scalability, improving affordability of CGTs, and expanding their access worldwide.
Learn more: https://www.linkedin.com/in/amrithajaishankar/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Boro Dropulić, CEO of Vector Biomed and Executive Director at Caring Cross.
Boro shares his vision of how decentralized manufacturing, low-cost vector production, and open-source workflows can make cell and gene therapies more accessible worldwide. They also discuss the role of digital technologies, partnerships, and innovative processes in overcoming industry bottlenecks, driving down costs, and expanding this access.
Learn more about Boro on LinkedIn
In this episode of the Ori Spotlight Podcast, Jason Foster is joined by Michael Krajewski, Director at Stand Back and an expert in engineering and scaling operations. Michael, with his background in aeronautics, brings a unique perspective on the Theory of Constraints and its role in CGT manufacturing processes.
Michael and Jason dive into the complex dynamics of bottlenecks and discuss how understanding constraints can pave the way for growth – without compromising efficiency. Together, they explore how manufacturing lessons from other industries can address the limitations faced by cell therapy today, and what it takes to streamline complex, regulated processes.
Learn more about Michael: https://www.linkedin.com/in/michael-krajewski/
In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs).
Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles.
Learn more about Carl: https://www.linkedin.com/in/carl-schoellhammer/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Anshul Mangal, President at Project Farma, to discuss the hurdles to scalable CGT development, the importance of early strategic planning, and the role of digitalization in improving efficiency and reducing costs.
Together they also highlight the potential of distributed manufacturing and the evolution of regulatory standards.
Anshul Mangal is a biotech entrepreneur and executive, leading Project Farma and Precision for Medicine's Manufacturing Solutions. He has pioneered the industrialization of early cell and gene therapies. Anshul also serves on the boards of the Alliance for Regenerative Medicines, Alliance for mRNA Medicines, and IQHQ, driving advancements in next-generation medicines.
Learn more about Anshul Mangal: https://www.linkedin.com/in/amangal/
In this episode, Omkar Kawalekar of Deloitte's NextGenTherapies practice joins Ori CEO Jason C. Foster, to explore the significance of technology and strategic collaborations in overcoming manufacturing challenges and developing advanced therapies at scale.
Their conversation covers key industry hurdles like supply chain optimization and the strategic planning necessary for bringing innovative treatments to market – offering insights into how the industry can achieve commercial viability and widespread patient access to CGTs.
Learn more about Omkar: https://www.linkedin.com/in/omkar-kawalekar-7406887/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Joe DePinto, head of Cell and Gene Advanced Therapies at McKesson, to discuss challenges and innovations in cell and gene therapy manufacturing and supply chains.
Together they also highlight the importance of collaborative partnerships and digital innovations to enhance access and streamline processes within the CGT sector.
Joe DePinto is a strategic and operational leader at McKesson, focusing on establishing the company as a market leader in cell, gene, and advanced therapies. With an extensive background in biotech and pharmaceuticals, Joe has helped companies pioneer advanced solutions in speciality healthcare.
Learn more about Joe DePinto: https://www.linkedin.com/in/joe-depinto-4a5b7b11/details/experience/
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Matthew Hewitt, Vice President and Technical Officer of Cell and Gene Therapy and Biologics at Charles River Laboratories, to discuss why industry collaboration is needed to experience the true impact of advanced therapies and develop them at a commercial scale. Together they also highlight the role of technology in closing, automating and scaling manufacturing processes.
Matthew has over 10 years of experience in the CGT sector, contributing to the advancement of CGTs across research and commercialization. As a member of our Strategic Advisory Board we're grateful for Matthew's insights as we work towards enabling widespread patient access to CGTs.
Learn more about Matthew Hewitt: https://www.linkedin.com/in/matthewmhewitt/
In this episode of the Ori Spotlight Podcast, host Jason C. Foster is joined by Jeff Holder and Adam Siebert from LEK Consulting, who offer an in-depth exploration of the evolving cell and gene therapy (CGT) industry.
LEK Consulting, a global leader in strategic advisory, aims to address the critical challenges of scalability and commercial viability within the CGT sector. Jeff and Adam, with their extensive background in life sciences consulting, share their insights on the importance of early investment in manufacturing processes to ensure that groundbreaking therapies can be delivered to patients efficiently and on a large scale.
Together they explore the intricacies of CGT production, the significance of early-stage manufacturing considerations, and their vision for making advanced therapies more accessible to those in need.
Learn more about:
Jeff Holder - https://www.linkedin.com/in/jeff-holder-ph-d-7a391087
Adam Siebert - https://www.linkedin.com/in/adam-siebert-8772b327/
In this episode of Ori Spotlight Podcast, we welcome Jim Faulkner, PhD, Independent Consultant at JDB BioConsulting and former SVP of Product Delivery at Autolus.
Jim brings a wealth of experience from his remarkable career in biopharmaceutical development and his journey in the industry is marked by significant contributions, particularly in pioneering cell therapy at GSK. The episode offers a deep dive into the evolving challenges in CGT manufacturing – centering on the critical challenges of scalability and commercial viability in CGTs – and sheds light on the unique demands and opportunities in the sector.
Learn more about Jim: https://www.linkedin.com/in/drjimfaulkner/
In this episode of the Ori Spotlight Podcast, we're joined by Sanjay Srivastava, Managing Director of Accenture's Cell and Gene Therapy Practice. With his extensive background in consulting and a deep understanding of the biotechnology sector, Sanjay offers unique insights into the rapidly evolving world of cell and gene therapies.
Sanjay and Jason C. Foster delve into the critical challenges facing the industry, particularly focusing on the scalability and efficiency of manufacturing processes. They discuss how these challenges impact the commercial viability of advanced therapies and the necessity of adapting our current healthcare systems to better accommodate innovative treatments.
Learn more about Sanjay here: https://www.linkedin.com/in/nitreniumions/
We’re joined by Tim Hunt, CEO of Alliance for Regenerative Medicine (ARM).
As an international advocacy organization, ARM is a global voice within the cell and gene therapy sector. They champion the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society as well as facilitating influential exchanges on policies and practices, and advances in narrative with data and analysis.
In this episode, Tim and Jason C. Foster discuss why it is important to put the patient first and where we should be focusing our attention to reduce the cost of goods and improve the accessibility of cell and gene therapies. Tim also offers his advice for people and companies working in the CGT space.
Learn more about Tim: https://www.linkedin.com/in/timhunt100/
We’re joined by Vered Caplan, CEO of Orgenesis, as she shares her insights into the cell and gene therapy sector.
With a background in engineering and business, Vered found her passion in the cell and gene therapy industry. She founded Orgenesis with a mission to bring innovative therapies to patients, by leveraging cutting-edge science to create a more efficient, scalable, and affordable pathway to patients.
In this episode, Vered discusses:
🧬 The need for greater adoption of technology to overcome manufacturing challenges of advanced therapies
🧬 Why digital is the key to tailoring manufacturing processes to the individual needs of patients
🧬 How industry partnerships support the scalability of therapy products
Learn more about Vered: https://www.linkedin.com/in/vered-caplan-4366928/
Comments
Download from Google Play
Download from App Store
United States